抗Aβ人源单链抗体基因的筛选和全抗体基因的构建及表达研究
发布时间：2018-09-11 21:46
【摘要】： 阿尔茨海默病(Alzheimer disease,AD)是一种以老年人中进行性记忆障碍和智能衰退为主要临床特征的中枢神经系统退行性疾病。老年斑(senile plaque,SP)、神经元纤维缠结(neurofibrillary tangles,NFT)和神经突触减少或神经元丢失是AD的主要病理特征。其中老年斑的主要成分是β-淀粉样多肽(beta-amyloidpeptide,Aβ)聚集形成的纤维,而Aβ纤维被认为是导致神经元损伤及认知功能衰退的主要致病物质。针对Aβ多肽在发病中的关键作用,研究如何阻止Aβ多肽聚集及清除大脑病变区已形成的Aβ多肽纤维已成为研究AD治疗的前沿领域,抗Aβ多肽抗体治疗AD也成为AD研究中的一个热点。动物试验已证明抗Aβ多肽抗体有清除小鼠大脑中Aβ纤维斑块防治AD的作用,但至今尚未见人源化抗体有临床应用的报道。 本课题研究从人源噬菌体单链抗体库中筛选针对Aβ的单链抗体可变区(scFv)基因,并以基因工程构建人源抗Aβ全抗体的真核表达体系。主要包括两部分:第一,从构建的人源噬菌体单链抗体库中筛选抗Aβ的scFv基因,在原核细胞中进行可溶性表达,并进行抗体结合活性和生物学活性检测;第二,重组IgG全抗体轻重链基因及全抗体单链基因,构建真核表达体系,进行真核细胞表达的初步研究。 一、抗Aβ人源scFv基因的筛选、原核表达与鉴定 以Aβ1-42多肽为抗原对抗体库进行4轮富集筛选:用辅助噬菌体M13K07感染E.coli TG1转化菌,展示出噬菌体形式的抗体库。将此抗体库加入到用Aβ1-42多肽包被的96孔板内,孵育一段时间后洗涤,能够与抗原特异结合的scFv噬菌体克隆将被保留在96孔板内壁,然后用pH 2.2的甘氨酸-HCl缓冲液将特异结合的噬菌体洗脱下来,经pH8.0的Tris-HCl中和后,感染处于对数生长期的E.coli TG1,以扩增抗原特异性噬菌体克隆。这样,经过4轮“吸附-洗脱-扩增”的富集过程,抗体库中与Aβ1-42多肽特异性结合的噬菌体克隆从第1轮的3.31×10~(-4)增加到第4轮的7.65×10~(-2),得到了高度富集,多克隆噬菌体Elisa检测也显示了明确的富集效果。随机挑取80个克隆,用M13K07感染后使scFv展示于噬菌体颗粒表面,ELISA筛选展示有抗Aβ1-42多肽scFv的噬菌体克隆。检测结果显示,得到7个阳性克隆,其中4个克隆ELISA检测A值高于阴性对照5倍以上,另外3个在2.5～3倍之间。所有阳性克隆均与无关抗原BSA无交叉反应。对其中A值最高的2个克隆(A10、F2)的噬菌体颗粒上清感染E.coli HB2151,30℃,IPTG诱导表达20h,分别制备胞周质、培养基上清和全细胞提取物。经12%SDS-PAGE和western blot分析,目的蛋白相对分子量为33kD,主要集中于全细胞提取物,表达量占全菌蛋白60%左右。表达抗体ELISA检测上清中和全菌蛋白中A值分别高于阴性对照5倍以上,在胞周质中高于2倍以上。抗体与Aβ1-40也有结合反应,但与BSA无交叉反应,显示scFv抗体对Aβ具有特异性,结合位点主要在Aβ的N端。表达抗体的生物学活性鉴定示,可与人脑病变组织内淀粉样斑块中的抗原物质Aβ纤维结合,证明表达的scFv抗体可以应用于体内生物学效应实验。将A10、F2克隆菌测序,用blast分析得到的scFv基因序列,从中分别确定了VH与VL的DNA序列,推导得到的氨基酸序列具有典型的抗体可变区结构。2个克隆的基因序列一致,表明2个克隆菌可能来源于同一株原始噬菌粒。 二、抗Aβ人源全抗体基因的重组构建、真核表达研究 首先对前期获得的A10克隆scFv基因进行NCBI blast比对,获得VH和VL基因相应的成熟信号肽基因,并合成信号肽基因,再设计特异引物分别扩增A10克隆的VH、VL、scFv基因和人源IgG的CH、CL、FC段基因,并利用重组PCR(overlap PCR)方法重组IgG全抗体重链基因(H信号肽基因+VH基因+CH基因)、IgG全抗体轻链基因(L信号肽基因+VL基因+CL基因)和全抗体单链基因(H信号肽基因+scFv基因+FC段基因),然后分别克隆到pcDNA3.1真核表达载体内。菌液PCR、双酶切鉴定和DNA测序结果均显示,重组的三种基因片段大小与预期一致,基因序列与预期的序列完全一致,读码框架和插入真核表达载体的方向完全正确。将IgG全抗体重链基因-载体质粒和IgG全抗体轻链基因-载体质粒共转染CHO细胞,表达IgG全抗体;将全抗体单链基因-载体质粒转染CHO细胞,表达单链全抗体(scFv抗体+FC段)。两种转染细胞初步的表达产物ELISA结果未见表达上清与Aβ1-42有阳性反应,后续工作仍需优化细胞表达条件。现有的工作进展为今后进一步优化表达、动物试验及应用研究奠定基础。 目前,虽然国内外已有几家筛选到人源抗Aβ抗体的报道,但都仍处于实验室研究阶段,也未见全抗体或进入临床试验的报道。我们所得到的抗Aβ序列经过比对,与现有已发表的抗Aβ抗体序列均不同,表明是一个新的抗Aβ抗体。现已在国内申报了专利,同时已完成了全抗体真核表达体系构建工作,后续的优化表达工作正在进行。本课题研究工作的结果有利于今后进一步开展对AD的免疫治疗和临床应用研究。
[Abstract]:Alzheimer disease (AD) is a degenerative disease of the central nervous system characterized by progressive memory impairment and mental decline in the elderly. Senile plaque (SP), neurofibrillary tangles (NFT) and neurosynapse loss are the main pathological features of AD. Sign. The main component of senile plaque is the fibers formed by the aggregation of beta-amyloid peptide (A beta), which is thought to be the main pathogenic substance leading to neuronal damage and cognitive decline. Anti-A-beta polypeptide antibody has been proved to be effective in clearing the plaque of A-beta fibers in the brain of mice to prevent and treat AD.
In this study, we screened the variable region (scFv) gene of single-chain antibody against A beta from human phage single-chain antibody library and constructed the eukaryotic expression system of human anti-A beta whole antibody by genetic engineering. Soluble expression and detection of antibody binding activity and biological activity; Secondly, recombinant IgG antibody light and heavy chain gene and antibody single chain gene, construct eukaryotic expression system, and preliminary study of eukaryotic expression.
I. screening, prokaryotic expression and identification of human A scFv gene
Four rounds of enrichment and screening of the antibody library against A-beta-1-42 polypeptide were carried out. E.coli TG1 transformed strain was infected with auxiliary phage M13K07 and phage-like antibody library was displayed. The phage library was added to 96-well plate coated with A-beta-42 polypeptide and washed after incubation for a period of time. The scFv phage clone which could specifically bind to the antigen was retained. After neutralization with Tris-HCl at pH 8.0, E.coli TG1, which was in logarithmic growth phase, was infected to amplify antigen-specific phage clones. Thus, after four rounds of "adsorption-elution-amplification" enrichment, the antibody library was specific to the peptide A-beta 1-42. Heterosexually bound phage clones were highly enriched from 3.31 (-4) in the first round to 7.65 (-2) in the fourth round. Polyclonal phage Elisa assay also showed a clear enrichment effect. Eighty clones were randomly selected and infected with M13K07, and scFv was displayed on the surface of phage particles. Anti-A1 1-42 peptide scFv was screened by ELISA. Phage cloning. The results showed that 7 positive clones were obtained, of which 4 clones were 5 times higher than those of the negative control and 3 clones were 2.5-3 times higher than those of the negative control. The relative molecular weight of the target protein was 33 kD, mainly concentrated in the whole cell extract, accounting for about 60% of the total bacterial protein. The A value in the supernatant and the whole bacterial protein detected by ELISA was 5 times higher than that in the negative control. The antibody also binds to A-beta 1-40, but does not cross-react with BSA. It shows that scFv antibody is specific to A-beta, and the binding site is mainly at the N-terminal of A-beta. The biological activity of the expressed antibody shows that it can bind to the antigen A-beta fibers in amyloid plaques of human brain lesions, which proves that the expressed scFv antibody is specific to A-beta. Fv antibody can be applied to biological effect test in vivo. The sequence of scFv gene from A10 and F2 clones was sequenced and analyzed by blast. The DNA sequences of VH and VL were determined respectively. The deduced amino acid sequences had typical antibody variable region structure. The sequences of the two clones were identical, which indicated that the two clones might originate from the same strain. Primordial bacteriophage.
Two, construction of recombinant human anti A beta antibody and eukaryotic expression.
Firstly, the mature signal peptide genes of VH and VL genes were obtained by NCBI blast, and the signal peptide genes were synthesized. Specific primers were designed to amplify the CH, CL, FC genes of A10 cloned VH, VL, scFv genes and human IgG, respectively. The recombinant PCR (overlap PCR) method was used to recombine the full-antibody heavy chain of IgG. The whole IgG antibody light chain gene (L signal peptide gene + VL gene + CL gene) and the whole antibody single chain gene (H signal peptide gene + scFv gene + FC segment gene) were cloned into the eukaryotic expression vector pcDNA3.1 respectively. The results of bacterial fluid PCR, double enzyme digestion and DNA sequencing showed that the recombinant three gene fragments were identified. The gene sequence was exactly the same as expected, and the reading frame and the direction of insertion into eukaryotic expression vector were completely correct. The results of ELISA showed no positive reaction between the supernatant of the two transfected cells and A-beta 1-42. Further work still needs to be done to optimize the cell expression conditions.
At present, there are several reports of screening human anti-A beta antibodies at home and abroad, but they are still in the stage of laboratory research, and there are no reports of full antibodies or clinical trials. The patents have been declared, and the construction of the eukaryotic expression system of the whole antibody has been completed. The subsequent optimization of the expression system is under way. The results of this study will be helpful for further research on immunotherapy and clinical application of AD.
【学位授予单位】：中国协和医科大学
【学位级别】：硕士
【学位授予年份】：2008
【分类号】：R392
本文编号：2237946
[Abstract]:Alzheimer disease (AD) is a degenerative disease of the central nervous system characterized by progressive memory impairment and mental decline in the elderly. Senile plaque (SP), neurofibrillary tangles (NFT) and neurosynapse loss are the main pathological features of AD. Sign. The main component of senile plaque is the fibers formed by the aggregation of beta-amyloid peptide (A beta), which is thought to be the main pathogenic substance leading to neuronal damage and cognitive decline. Anti-A-beta polypeptide antibody has been proved to be effective in clearing the plaque of A-beta fibers in the brain of mice to prevent and treat AD.
In this study, we screened the variable region (scFv) gene of single-chain antibody against A beta from human phage single-chain antibody library and constructed the eukaryotic expression system of human anti-A beta whole antibody by genetic engineering. Soluble expression and detection of antibody binding activity and biological activity; Secondly, recombinant IgG antibody light and heavy chain gene and antibody single chain gene, construct eukaryotic expression system, and preliminary study of eukaryotic expression.
I. screening, prokaryotic expression and identification of human A scFv gene
Four rounds of enrichment and screening of the antibody library against A-beta-1-42 polypeptide were carried out. E.coli TG1 transformed strain was infected with auxiliary phage M13K07 and phage-like antibody library was displayed. The phage library was added to 96-well plate coated with A-beta-42 polypeptide and washed after incubation for a period of time. The scFv phage clone which could specifically bind to the antigen was retained. After neutralization with Tris-HCl at pH 8.0, E.coli TG1, which was in logarithmic growth phase, was infected to amplify antigen-specific phage clones. Thus, after four rounds of "adsorption-elution-amplification" enrichment, the antibody library was specific to the peptide A-beta 1-42. Heterosexually bound phage clones were highly enriched from 3.31 (-4) in the first round to 7.65 (-2) in the fourth round. Polyclonal phage Elisa assay also showed a clear enrichment effect. Eighty clones were randomly selected and infected with M13K07, and scFv was displayed on the surface of phage particles. Anti-A1 1-42 peptide scFv was screened by ELISA. Phage cloning. The results showed that 7 positive clones were obtained, of which 4 clones were 5 times higher than those of the negative control and 3 clones were 2.5-3 times higher than those of the negative control. The relative molecular weight of the target protein was 33 kD, mainly concentrated in the whole cell extract, accounting for about 60% of the total bacterial protein. The A value in the supernatant and the whole bacterial protein detected by ELISA was 5 times higher than that in the negative control. The antibody also binds to A-beta 1-40, but does not cross-react with BSA. It shows that scFv antibody is specific to A-beta, and the binding site is mainly at the N-terminal of A-beta. The biological activity of the expressed antibody shows that it can bind to the antigen A-beta fibers in amyloid plaques of human brain lesions, which proves that the expressed scFv antibody is specific to A-beta. Fv antibody can be applied to biological effect test in vivo. The sequence of scFv gene from A10 and F2 clones was sequenced and analyzed by blast. The DNA sequences of VH and VL were determined respectively. The deduced amino acid sequences had typical antibody variable region structure. The sequences of the two clones were identical, which indicated that the two clones might originate from the same strain. Primordial bacteriophage.
Two, construction of recombinant human anti A beta antibody and eukaryotic expression.
Firstly, the mature signal peptide genes of VH and VL genes were obtained by NCBI blast, and the signal peptide genes were synthesized. Specific primers were designed to amplify the CH, CL, FC genes of A10 cloned VH, VL, scFv genes and human IgG, respectively. The recombinant PCR (overlap PCR) method was used to recombine the full-antibody heavy chain of IgG. The whole IgG antibody light chain gene (L signal peptide gene + VL gene + CL gene) and the whole antibody single chain gene (H signal peptide gene + scFv gene + FC segment gene) were cloned into the eukaryotic expression vector pcDNA3.1 respectively. The results of bacterial fluid PCR, double enzyme digestion and DNA sequencing showed that the recombinant three gene fragments were identified. The gene sequence was exactly the same as expected, and the reading frame and the direction of insertion into eukaryotic expression vector were completely correct. The results of ELISA showed no positive reaction between the supernatant of the two transfected cells and A-beta 1-42. Further work still needs to be done to optimize the cell expression conditions.
At present, there are several reports of screening human anti-A beta antibodies at home and abroad, but they are still in the stage of laboratory research, and there are no reports of full antibodies or clinical trials. The patents have been declared, and the construction of the eukaryotic expression system of the whole antibody has been completed. The subsequent optimization of the expression system is under way. The results of this study will be helpful for further research on immunotherapy and clinical application of AD.
【学位授予单位】：中国协和医科大学
【学位级别】：硕士
【学位授予年份】：2008
【分类号】：R392
【参考文献】
相关期刊论文 前3条
1 夏骏,李晓宇,陈秀英,范乐明,陈琪;β淀粉样多肽人源性抗体的筛选与鉴定[J];南京医科大学学报(自然科学版);2004年04期
2 张梅,司履生;重组PCR——一种快速体外基因重组技术[J];西安医科大学学报;2001年03期
3 蔡炯,王世真,彭勇,钟彦伟,姬志娟,袁建刚,强伯勤;阿尔茨海默病Aβ人抗体可变区片段基因的克隆和表达[J];中国医学科学院学报;2003年05期
，本文编号：2237946
本文链接：https://www.wllwen.com/yixuelunwen/shiyanyixue/2237946.html
最近更新
教材专著
